Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Vergani E, et al. Among authors: perrone f. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. Oncotarget. 2016. PMID: 26684239 Free PMC article.
BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M. Daniotti M, et al. Among authors: perrone f. Oncogene. 2004 Aug 5;23(35):5968-77. doi: 10.1038/sj.onc.1207780. Oncogene. 2004. PMID: 15195137
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S. Tamborini E, et al. Among authors: perrone f. Clin Cancer Res. 2006 Dec 1;12(23):6920-8. doi: 10.1158/1078-0432.CCR-06-1584. Clin Cancer Res. 2006. PMID: 17145809
Targeted therapies: the rare cancer paradigm.
Pierotti MA, Negri T, Tamborini E, Perrone F, Pricl S, Pilotti S. Pierotti MA, et al. Among authors: perrone f. Mol Oncol. 2010 Feb;4(1):19-37. doi: 10.1016/j.molonc.2009.10.003. Epub 2009 Oct 28. Mol Oncol. 2010. PMID: 19913465 Free PMC article. Review.
Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G, Gasparini P, Cavazza A, Rossi G, Graziano P, Barbareschi M, Perrone F, Barberis M, Takagi M, Kunimura T, Yamada T, Nakatani Y, Pastorino U, Scanagatta P, Sozzi G, Garassino M, De Braud F, Papotti M. Pelosi G, et al. Among authors: perrone f. Lung Cancer. 2012 Sep;77(3):507-14. doi: 10.1016/j.lungcan.2012.05.093. Epub 2012 Jun 16. Lung Cancer. 2012. PMID: 22705117
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen.
Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. Pietrantonio F, et al. Among authors: perrone f. Transl Oncol. 2012 Jun;5(3):155-9. doi: 10.1596/tlo.12151. Epub 2012 Jun 1. Transl Oncol. 2012. PMID: 22741034 Free PMC article.
A review on biomarkers for prediction of treatment outcome in gastric cancer.
Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. Pietrantonio F, et al. Among authors: perrone f. Anticancer Res. 2013 Apr;33(4):1257-66. Anticancer Res. 2013. PMID: 23564763 Free article. Review.
682 results